agilon health, inc. Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid
agilon health, inc. (AGL) reported Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid of $2.47 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForLossesAndLossAdjustmentExpense · last filed 2026-08-05
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for the quarter ending 2026-06-30 was $1.32B, a 13.38% decline year-over-year.
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for the quarter ending 2026-03-31 was $1.15B, a 6.00% decline year-over-year.
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for the quarter ending 2025-12-31 was $1.78B, a 0.16% decline year-over-year.
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for the quarter ending 2025-09-30 was $1.47B, a 4.37% increase year-over-year.
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for fiscal 2025 was $6.00B, a 6.27% increase from fiscal 2024.
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for fiscal 2024 was $5.65B, a 44.97% increase from fiscal 2023.
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for fiscal 2023 was $3.90B, a 69.44% increase from fiscal 2022.
- agilon health, inc. liability for unpaid claims and claims adjustment expense, claims paid for fiscal 2022 was $2.30B, a 46.26% increase from fiscal 2021.
| Period end | Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid 3 month | Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid 6 month | Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid 9 month | Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.32B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.47B 10-Q · filed 2026-08-05 | $4.25B derived: sum of 3 quarters · filed 2026-08-05 | $5.72B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.15B 10-Q · filed 2026-05-06 | $2.93B derived: sum of 2 quarters · filed 2026-05-06 | $4.40B derived: sum of 3 quarters · filed 2026-05-06 | $5.93B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.78B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.25B derived: sum of 2 quarters · filed 2026-02-25 | $4.78B derived: sum of 3 quarters · filed 2026-08-05 | $6.00B 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.47B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.00B derived: sum of 2 quarters · filed 2026-08-05 | $4.22B 10-Q · filed 2025-11-04 | $6.00B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.53B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.75B 10-Q · filed 2026-08-05 | $4.53B derived: sum of 3 quarters · filed 2026-08-05 | $5.94B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.22B 10-Q · filed 2026-05-06 | $3.00B derived: sum of 2 quarters · filed 2026-05-06 | $4.41B derived: sum of 3 quarters · filed 2026-05-06 | $5.96B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.78B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.19B derived: sum of 2 quarters · filed 2026-02-25 | $4.74B derived: sum of 3 quarters · filed 2026-02-25 | $5.65B 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.41B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.96B derived: sum of 2 quarters · filed 2025-11-04 | $3.87B 10-Q · filed 2025-11-04 | $5.33B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.54B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $2.46B 10-Q · filed 2025-08-04 | $3.92B derived: sum of 3 quarters · filed 2026-02-25 | $5.12B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $912.03M 10-Q · filed 2025-05-06 | $2.37B derived: sum of 2 quarters · filed 2026-02-25 | $3.57B derived: sum of 3 quarters · filed 2026-02-25 | $4.23B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $1.46B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.66B derived: sum of 2 quarters · filed 2026-02-25 | $3.32B derived: sum of 3 quarters · filed 2026-02-25 | $3.90B 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.20B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.85B derived: sum of 2 quarters · filed 2024-11-07 | $2.43B 10-Q · filed 2024-11-07 | $3.21B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $655.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.23B 10-Q · filed 2024-08-06 | $2.01B derived: sum of 3 quarters · filed 2025-02-25 | $2.60B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $579.05M 10-Q · filed 2024-05-07 | $1.36B derived: sum of 2 quarters · filed 2025-02-25 | $1.94B derived: sum of 3 quarters · filed 2025-02-25 | |
| 2022-12-31 | $779.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.37B derived: sum of 2 quarters · filed 2025-02-25 | $2.30B 10-K · filed 2025-02-25 | |
| 2022-09-30 | $585.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.52B 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $934.10M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $1.57B 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |